Effect of Diltiazem on Coronary Artery Ectasia
Information source: Ankara University
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Coronary Artery Ectasia
Intervention: intracoronary administration of diltiazem (Drug); intracoronary injection of 5 mL saline (Drug)
Phase: N/A
Status: Completed
Sponsored by: Ankara University
Summary
Coronary artery ectasia (CAE) has been defined as localized or diffuse dilatation of
epicardial coronary arteries more than 1. 5 fold of adjacent normal segments. Isolated CAE
constitutes minor portion of the total CAE cases, with an incidence of 0. 1% to 0. 79% in
which coronary artery stenosis or severe valvular heart diseases are not present. CAE
represents not only an anatomical variant but also a clinical constellation of coronary
artery disease (CAD) like association with myocardial ischemia and acute coronary syndromes.
Patients with CAE without significant coronary narrowing may still present with angina
pectoris, positive stress tests, or acute coronary syndromes. Impaired epicardial and
microvascular perfusion were demonstrated in ectatic coronary arteries.
Myocardial blush grading (MBG) technique has been utilized in various conditions such as
acute myocardial infarction, coronary artery ectasia, syndrome X and idiopathic dilated
cardiomyopathy to evaluate myocardial perfusion.
There is still no consensus for management of CAE. Previously improvement of coronary flow
has been demonstrated by mibefradil in patients with slow coronary flow. A new trial is
needed to explore the effect of calcium channel blockers (CCB) in isolated CAE. Diltiazem
improves myocardial perfusion by blocking calcium channels in coronary arteries. This agent
has been widely used in coronary catheter labs to prevent and treat no-reflow.
The current study with prospective design was therefore set up to assess whether epicardial
flow and tissue level perfusion would be improved by diltiazem in myocardial regions
subtended by the ectatic coronary arteries among patients with isolated CAE.
Clinical Details
Official title: Short Term Effect of Diltiazem on Myocardial Perfusion in Patients With Isolated Coronary Artery Ectasia- a Prospective Clinical Study
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic
Primary outcome: Myocardial blush gradeTIMI (Thrombolysis in myocardial infarction) flow grade TIMI (Thrombolysis in myocardial infarction) frame count
Eligibility
Minimum age: 18 Years.
Maximum age: 80 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria: Patients with isolated coronary artery ectasia at least 1 major
epicardial coronary artery
Exclusion Criteria:
Patients with known allergy to diltiazem acute coronary syndrome left ventricular systolic
dysfunction significant valvular heart disease heart failure systolic blood pressure <90
mmHg heart rate <60 atrioventricular block (grade > I) severe liver or kidney failure
significant coronary artery stenosis and patients on treatment with calcium channel
blockers were excluded
Locations and Contacts
Ankara University School Of Medicine, Department of Cardiology, Ankara 06230, Turkey
Additional Information
Starting date: June 2012
Last updated: May 5, 2015
|